ILC 2019: UK population-based study finds large numbers of young adults have nonalcoholic fatty liver disease (NAFLD) and many of these already have fibrosis 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A large…
ILC 2019: Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) An interim…
ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) The increasing burden and…
ILC 2019: New studies in Germany and France support the need for early detection and effective interventions among NAFLD/NASH patients 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) Two independent national studies have reported…
ILC 2019: Italian study reveals high cost of advanced liver disease in NAFLD/NASH patients and missed opportunities to diagnose earlier, yet screening high-risk individuals for NAFLD may not be cost effective if treatments are too expensive 11 April 2019, Vienna,…
ILC 2019: Interim analysis of the Phase 3 REGENERATE study suggests that obeticholic acid holds promise as a future treatment for NASH. 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A prespecified interim analysis…